{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:10:17Z","timestamp":1790691017082,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tmrv.2026.151045","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:18:04Z","timestamp":1788949084000},"page":"151045","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Potential Impact of Undisclosed Use of HIV Treatment and Prevention Antiretrovirals on Blood Safety"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3217-5898","authenticated-orcid":false,"given":"Renata","family":"Buccheri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7046-7245","authenticated-orcid":false,"given":"Eduard","family":"Grebe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Custer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2026.151045_bib0001","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/vox.13011","article-title":"Effect of HIV pre-exposure prophylaxis (PrEP) on detection of early infection and its impact on the appropriate post-PrEP deferral period","volume":"116","author":"Seed","year":"2021","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2026.151045_bib0002","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1097\/00002030-200309050-00005","article-title":"Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection","volume":"17","author":"Fiebig","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2026.151045_bib0003","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1056\/NEJMra1011874","article-title":"Acute HIV-1 infection","volume":"364","author":"Cohen","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0004","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s11904-014-0251-7","article-title":"HIV testing updates and challenges: when regulatory caution and public health imperatives collide","volume":"12","author":"Branson","year":"2015","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.tmrv.2026.151045_bib0005","series-title":"Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy","year":"2017"},{"key":"10.1016\/j.tmrv.2026.151045_bib0006","series-title":"Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 update: a clinical practice guideline","year":"2021"},{"key":"10.1016\/j.tmrv.2026.151045_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25419","article-title":"Challenges of HIV diagnosis and management in the context of pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review","volume":"22","author":"Elliott","year":"2019","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.tmrv.2026.151045_bib0008","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1046\/j.1537-2995.2002.00174.x","article-title":"Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population","volume":"42","author":"Dodd","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0009","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1111\/trf.15203","article-title":"Transfusion of HIV-infected blood products despite highly sensitive nucleic acid testing","volume":"59","author":"Cappy","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0010","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1046\/j.1537-2995.2002.00200.x","article-title":"International application of the incidence rate\/window period model","volume":"42","author":"Glynn","year":"2002","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0011","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/jama.284.2.210","article-title":"Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period","volume":"284","author":"Ling","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2026.151045_bib0012","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1309\/GBLA-NL8D-3277-XUP1","article-title":"HIV transmissions from a window-period platelet donation","volume":"116","author":"Kopko","year":"2001","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.tmrv.2026.151045_bib0013","article-title":"Detection of HIV-1 infections in blood donors during the pre-seroconversion window period in S\u00e3o Paulo","volume":"52","author":"Salles","year":"2019","journal-title":"brazil. Rev Soc Bras Med Trop"},{"key":"10.1016\/j.tmrv.2026.151045_bib0014","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1097\/QAD.0000000000002947","article-title":"Lack of HIV seroconversion in a patient treated immediately with antiretroviral therapy at acute infection and virus relapse","volume":"35","author":"Pasticci","year":"2021","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2026.151045_bib0015","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/ciw365","article-title":"Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of nonreactive HIV serology","volume":"63","author":"De Souza","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmrv.2026.151045_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00757-19","article-title":"Decreased seroreactivity in individuals initiating antiretroviral therapy during acute HIV infection","volume":"57","author":"Manak","year":"2019","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.tmrv.2026.151045_bib0017","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1742-6405-3-3","article-title":"Absence of seroreversion in 80 HAART-treated HIV-1 seropositive patients with at least five-years undetectable plasma HIV-1 viral load","volume":"3","author":"Cornelissen","year":"2006","journal-title":"AIDS Res Ther"},{"key":"10.1016\/j.tmrv.2026.151045_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104414","article-title":"Reduction of anti-HIV antibody responses in subjects receiving antiretroviral therapy during chronic HIV-1 infection","volume":"128","author":"Liang","year":"2020","journal-title":"J Clin Virol Off Publ Pan Am Soc Clin Virol"},{"key":"10.1016\/j.tmrv.2026.151045_bib0019","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0020","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/infdis\/jiab152","article-title":"Characterization of human immunodeficiency virus (HIV) infection in cisgender men and transgender women who have sex with men receiving injectable cabotegravir for HIV prevention: HPTN 083","volume":"224","author":"Marzinke","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmrv.2026.151045_bib0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant","year":"2014","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.tmrv.2026.151045_bib0022","doi-asserted-by":"crossref","first-page":"e166","DOI":"10.1016\/S2352-3018(20)30271-X","article-title":"Primary HIV-1 infection in users of pre-exposure prophylaxis","volume":"8","author":"Ambrosioni","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2026.151045_bib0023","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/S2352-3018(17)30132-7","article-title":"Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report","volume":"4","author":"Hoornenborg","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2026.151045_bib0024","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1097\/QAD.0000000000001577","article-title":"The effect of oral preexposure prophylaxis on the progression of HIV-1 seroconversion","volume":"31","author":"Donnell","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.tmrv.2026.151045_bib0025","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hiv.12989","article-title":"A review of reported cases of HIV pre-exposure prophylaxis failure with resultant breakthrough HIV infections","volume":"22","author":"To","year":"2021","journal-title":"HIV Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/QAI.0000000000001374","article-title":"Characterization of HIV seroconverters in a TDF\/FTC PrEP study: HPTN 067\/ADAPT","volume":"75","author":"Sivay","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.tmrv.2026.151045_bib0027","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","article-title":"Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial","volume":"399","author":"Delany-Moretlwe","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2026.151045_bib0028","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S2352-3018(23)00261-8","volume":"10","author":"Landovitz","year":"2023","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2026.151045_bib0029","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002690","article-title":"Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial","volume":"15","author":"Landovitz","year":"2018","journal-title":"PLoS Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0030","doi-asserted-by":"crossref","first-page":"e472","DOI":"10.1016\/S2352-3018(20)30106-5","article-title":"Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial","volume":"7","author":"Landovitz","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tmrv.2026.151045_bib0031","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","article-title":"Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women","volume":"391","author":"Bekker","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0032","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","article-title":"Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons","volume":"392","author":"Kelley","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0142534","article-title":"Adherence to post-exposure prophylaxis (PEP) and incidence of HIV seroconversion in a major North American cohort","volume":"10","author":"Thomas","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.tmrv.2026.151045_bib0034","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/trf.18275","article-title":"Performance of a whole blood immunoassay for tenofovir detection and correlation with self-reported pre-exposure prophylaxis use in HIV -negative men who have sex with men interested in blood donation","volume":"65","author":"Buccheri","year":"2025","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0035","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11904-020-00512-3","article-title":"Point-of-care and near real-time testing for antiretroviral adherence monitoring to HIV treatment and prevention","volume":"17","author":"Drain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"10.1016\/j.tmrv.2026.151045_bib0036","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/infdis\/jiz145","article-title":"Discovery of false elite controllers: HIV antibody-positive RNA-negative blood donors found to Be on antiretroviral therapy","volume":"220","author":"Sykes","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmrv.2026.151045_bib0037","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood.2020006890","article-title":"HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern","volume":"136","author":"Custer","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2026.151045_bib0038","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/sextrans-2021-054981","article-title":"Evidence of HIV pre-exposure or post-exposure prophylaxis (PrEP\/PEP) among blood donors: a pilot study, England June 2018 to July 2019","volume":"98","author":"Harvala","year":"2022","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.tmrv.2026.151045_bib0039","doi-asserted-by":"crossref","DOI":"10.1111\/vox.70232","article-title":"Pre-exposure prophylaxis use in blood donors in England","author":"Debrah","year":"2026","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2026.151045_bib0040","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1111\/trf.17941","article-title":"Blood safety markers in Dutch donors after relaxation of deferral for men who have sex with men: re-emergence of syphilis and HIV pre-exposure prophylaxis use","volume":"64","author":"Quee","year":"2024","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0041","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1111\/trf.18393","article-title":"Nondisclosure of use of antiretroviral medications in Canadian blood donors","volume":"65","author":"Goldman","year":"2025","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0042","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/trf.17544","article-title":"Detection of unreported usage of the antiretroviral drug lamivudine in two blood donors","volume":"63","author":"Nishiya","year":"2023","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0043","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1111\/trf.16698","article-title":"Influence of unreported HIV prophylaxis on the kinetics of post-blood donation HIV seroconversion","volume":"61","author":"Nishiya","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0044","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/tme.12957","article-title":"Motivations for blood donation by HIV-positive individuals on antiretrovirals in South Africa: a qualitative study","volume":"33","author":"Van Den Berg","year":"2023","journal-title":"Transfus Med"},{"key":"10.1016\/j.tmrv.2026.151045_bib0045","first-page":"110","article-title":"Development of a risk assessment model of HIV transfusion transmission associated with undisclosed use of pre-exposure prophylaxis (PrEP) by blood donors","volume":"120","author":"Grebe","year":"2025","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2026.151045_bib0046","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1537-2995.2004.04215.x","article-title":"A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors","volume":"45","author":"Busch","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0047","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1537-2995.2010.02804.x","article-title":"Refinement of a viral transmission risk model for blood donations in seroconversion window phase screened by nucleic acid testing in different pool sizes and repeat test algorithms","volume":"51","author":"Weusten","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0048","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/QAI.0000000000003115","article-title":"Modeling the risk of HIV transfusion transmission","volume":"92","author":"Belov","year":"2023","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.tmrv.2026.151045_bib0049","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1111\/trf.16571","article-title":"Undisclosed HIV status and antiretroviral therapy use among South African blood donors","volume":"61","author":"Van den Berg","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2026.151045_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107222","article-title":"Suppressed HIV antibody responses following exposure to antiretrovirals\u2014evidence from PrEP randomized trials and early antiretroviral treatment initiation studies","volume":"148","author":"Avelino-Silva","year":"2024","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tmrv.2026.151045_bib0051","doi-asserted-by":"crossref","DOI":"10.1128\/jcm.01273-25","article-title":"HIV serologic reactivity varies with time of ART initiation in persons on long-term ART","volume":"64","author":"Avelino-Silva","year":"2026","journal-title":"J Clin Microbiol"}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796326000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796326000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:52:18Z","timestamp":1790689938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796326000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S0887796326000866"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2026.151045","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Potential Impact of Undisclosed Use of HIV Treatment and Prevention Antiretrovirals on Blood Safety","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2026.151045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"151045"}}